$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come
It was Axel Bolte’s work as a venture partner for HBM that originally took him to the campus at Yale, with a chance to start …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
